SCOCO Activators
SCOCO activators are a group of chemical compounds that have the potential to enhance its functional activity through their influence on specific signaling pathways. These compounds largely target the PI3K/AKT/mTOR and MAPK pathways, which are interconnected with the activity of SCOCO. PI3K inhibitors like LY294002, AKT inhibitor Triciribine, and mTOR inhibitors like Rapamycin, Apigenin, and WYE-354, can potentially enhance SCOCO activity through a compensatory mechanism when the PI3K/AKT/mTORpathway is inhibited.
Similarly, the MEK inhibitors PD98059, U0126, and Selumetinib, the JNK inhibitor SP600125, and the p38 MAPK inhibitor SB203580 can potentially affect SCOCO activity through a similar compensatory mechanism within the MAPK pathway. The rationale is that the inhibition of these pathways might result in an upregulation of SCOCO activity to maintain cellular equilibrium.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks), which are upstream regulators of AKT signaling pathway. SCOCO, known to interact with AKT, might get activated when the AKT pathway is affected. With LY294002 inhibiting PI3K, AKT activation will be dampened, potentially causing a compensatory increase in SCOCO activation to maintain cellular homeostasis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of mammalian target of rapamycin (mTOR), a central regulator of cellular metabolism and growth. Since SCOCO is interconnected with the mTOR pathway through AKT, inhibition of mTOR by Rapamycin might cause a compensatory increase in SCOCO activation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an inhibitor of AKT, a key node in the PI3K/AKT/mTOR pathway. Since SCOCO is known to interact with AKT, inhibition of AKT might result in an upregulation of SCOCO activity to maintain cellular equilibrium. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, a kinase upstream of ERK in the MAPK pathway. As SCOCO interacts with AKT, which is also known to be influenced by cross-talk from the MAPK pathway, this could lead to enhanced SCOCO activity following MAPK pathway inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinases (JNKs), which are members of the MAPK family. SCOCO, known to interact with AKT, might get indirectly activated when JNKs are inhibited due to the interconnectedness of signaling pathways. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB203580 inhibits p38 MAPK, a member of the MAPK family. Inhibition of p38 could lead to enhanced SCOCO activity due to the interconnectedness of cellular signaling pathways and SCOCO's known interaction with AKT. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor, which targets the MAPK pathway. The inhibition of this pathway could lead to enhanced SCOCO activity due to the cross-talk between the MAPK and AKT pathways, where SCOCO plays a role. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $32.00 $210.00 $720.00 $1128.00 $2302.00 $3066.00 $5106.00 | 22 | |
Apigenin is a bioflavonoid that inhibits mTOR, a key component in the PI3K/AKT/mTOR pathway. By inhibiting mTOR, Apigenin might indirectly lead to enhanced SCOCO activity due to the interconnectedness of these signaling pathways. | ||||||
WYE-354 | 1062169-56-5 | sc-364652 sc-364652A | 10 mg 50 mg | $286.00 $1200.00 | ||
WYE-354 is an mTOR inhibitor that targets the PI3K/AKT/mTOR pathway. Inhibition of mTOR could lead to enhanced SCOCO activity due to the cross-talk between these signaling pathways. | ||||||